Literature DB >> 2927156

Carcinoma of the lung. Evaluation of satellite nodules as a factor influencing prognosis after resection.

J Deslauriers1, J Brisson, R Cartier, M Fournier, D Gagnon, M Piraux, M Beaulieu.   

Abstract

Satellite nodules are considered to be predictive of poor prognosis in breast cancer and in melanoma. In lung cancer, there is no information as to their definition, prevalence, or implication as a prognosis factor of survival after resection. Over the past 18 years (1969 to 1987), 84 patients underwent pulmonary resection for primary lung cancer accompanied by satellite nodules. These nodules were defined as well-circumscribed accessory carcinoma foci clearly separated from the main tumor but with identical histologic characteristics. All were smaller than the primary carcinoma and most were located within the same lobe. Survival rates of patients with satellite nodules were compared to those of 1021 patients without satellite nodules who underwent resection during the same time interval. The 1-, 3-, and 5-year survival rates for all patients classified as having no satellite nodules were 78%, 54%, and 44%, respectively, and the median survival for the entire group was 30 months. In patients with satellite nodules, these survival rates were 60.9%, 32.7%, and 21.6%, respectively, with a median survival of 15 months. The deleterious effect of satellite nodules was more significant in patients with stage I disease (p = 0.0008) than in patients with stage II (p = 0.0354) or stage III (p = 0.0145) disease. Survival data obtained by comparison of satellite nodule status and histologic characteristics shows that 5-year survival figures are better for patients with no satellite nodules in both the squamous and the nonsquamous groups. This study demonstrates that satellite nodules associated with lung cancer are indicative of locally advanced and/or premetastatic disease. These patients should be included in the stage group IIIa of the TNM stage grouping classification.

Entities:  

Mesh:

Year:  1989        PMID: 2927156

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  8 in total

1.  Surgical treatment for non-small cell lung cancer with ipsilateral pulmonary metastases.

Authors:  Tatsuro Okamoto; Takekazu Iwata; Teruaki Mizobuchi; Hidehisa Hoshino; Yasumitsu Moriya; Shigetoshi Yoshida; Ichiro Yoshino
Journal:  Surg Today       Date:  2012-12-10       Impact factor: 2.549

Review 2.  Extended resection for higher-stage non-small-cell lung cancer.

Authors:  J D Luketich; D E van Raemdonck; R J Ginsberg
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

Review 3.  The role of surgery in the treatment of stage III non-small-cell lung cancer.

Authors:  Amy E Gallo; Jessica S Donington
Journal:  Curr Oncol Rep       Date:  2007-07       Impact factor: 5.075

Review 4.  Non-small-cell lung carcinoma. Current and future therapeutic management.

Authors:  K T Bastin; R Curley
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

Review 5.  Management of locally advanced non small cell lung cancer from a surgical perspective.

Authors:  Millie S Roy; Jessica S Donington
Journal:  Curr Treat Options Oncol       Date:  2007-02

6.  Genomic heterogeneity of multiple synchronous lung cancer.

Authors:  Yu Liu; Jianjun Zhang; Lin Li; Guangliang Yin; Jianhua Zhang; Shan Zheng; Hannah Cheung; Ning Wu; Ning Lu; Xizeng Mao; Longhai Yang; Jiexin Zhang; Li Zhang; Sahil Seth; Huang Chen; Xingzhi Song; Kan Liu; Yongqiang Xie; Lina Zhou; Chuanduo Zhao; Naijun Han; Wenting Chen; Susu Zhang; Longyun Chen; Wenjun Cai; Lin Li; Miaozhong Shen; Ningzhi Xu; Shujun Cheng; Huanming Yang; J Jack Lee; Arlene Correa; Junya Fujimoto; Carmen Behrens; Chi-Wan Chow; William N William; John V Heymach; Waun Ki Hong; Stephen Swisher; Ignacio I Wistuba; Jun Wang; Dongmei Lin; Xiangyang Liu; P Andrew Futreal; Yanning Gao
Journal:  Nat Commun       Date:  2016-10-21       Impact factor: 14.919

7.  [Anatomy, biology and concepts, pertaining to lung cancer stage classification].

Authors:  Frank C Detterbeck; Lynn T Tanoue; Daniel J Boffa
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-01

8.  Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers.

Authors:  Erin M Corsini; Jinliang Wang; Chia-Chin Wu; Junya Fujimoto; Marcelo V Negrao; Runzhe Chen; Kelly Quek; Kyle G Mitchell; Chi-Wan B Chow; Latasha Little; Curtis Gumbs; Xingzhi Song; Carmen Behrens; Arlene M Correa; Mara B Antonoff; Stephen G Swisher; John V Heymach; Jianhua Zhang; Ignacio I Wistuba; P Andrew Futreal; Boris Sepesi; Jianjun Zhang
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.